Have your own idea? Try our Stock Screener
The Life Sciences industry is up 1.9% in the last week, with EirGenix up 5.4%. Meanwhile, TFBS Bioscience actually underperformed within the industry, shrinking 19% in the last week. In contrast, the industry has lost 25% in the last 12 months. As for the next few years, earnings are expected to grow by 38% per annum.
Has the Taiwanese Life Sciences Industry valuation changed over the past few years?
Date | Market Cap | Revenue | Earnings | PE | Absolute PE | PS |
---|---|---|---|---|---|---|
Sun, 22 Dec 2024 | NT$34.3b | NT$2.6b | -NT$854,432,000.00 | 24.5x | -40.2x | 13.4x |
Tue, 19 Nov 2024 | NT$40.2b | NT$2.6b | -NT$847,398,000.00 | 23.7x | -47.5x | 15.7x |
Thu, 17 Oct 2024 | NT$40.7b | NT$2.3b | -NT$836,610,000.00 | 22.6x | -48.6x | 17.9x |
Sat, 14 Sep 2024 | NT$40.3b | NT$2.3b | -NT$836,610,000.00 | 21.7x | -48.2x | 17.7x |
Mon, 12 Aug 2024 | NT$39.3b | NT$2.1b | -NT$791,513,000.00 | 27.9x | -49.7x | 18.5x |
Wed, 10 Jul 2024 | NT$44.1b | NT$2.1b | -NT$797,765,000.00 | 33.7x | -55.3x | 20.7x |
Fri, 07 Jun 2024 | NT$40.3b | NT$2.1b | -NT$797,765,000.00 | 32.7x | -50.5x | 18.9x |
Sun, 05 May 2024 | NT$39.8b | NT$2.1b | -NT$914,899,000.00 | 32.4x | -43.5x | 18.8x |
Tue, 02 Apr 2024 | NT$40.7b | NT$2.1b | -NT$903,875,000.00 | 31.9x | -45x | 19.3x |
Thu, 29 Feb 2024 | NT$44.0b | NT$2.1b | -NT$610,218,000.00 | 33.5x | -72x | 21.2x |
Sat, 27 Jan 2024 | NT$44.3b | NT$2.1b | -NT$610,218,000.00 | 33.1x | -72.6x | 21.3x |
Mon, 25 Dec 2023 | NT$47.2b | NT$2.1b | -NT$610,218,000.00 | 33.5x | -77.3x | 22.7x |
Wed, 22 Nov 2023 | NT$47.8b | NT$2.1b | -NT$609,632,000.00 | 31.1x | -78.5x | 23x |
Fri, 20 Oct 2023 | NT$46.4b | NT$2.2b | -NT$497,769,000.00 | 31x | -93.3x | 20.9x |
Sun, 17 Sep 2023 | NT$44.1b | NT$2.2b | -NT$497,769,000.00 | 31x | -88.5x | 19.8x |
Tue, 15 Aug 2023 | NT$42.7b | NT$2.2b | -NT$491,561,000.00 | 39.9x | -86.8x | 19.1x |
Thu, 13 Jul 2023 | NT$47.7b | NT$2.5b | -NT$274,767,000.00 | 42.8x | -173.7x | 19.5x |
Sat, 10 Jun 2023 | NT$49.3b | NT$2.5b | -NT$274,767,000.00 | 43.1x | -179.5x | 20.1x |
Mon, 08 May 2023 | NT$53.0b | NT$2.7b | -NT$29,017,000.00 | 24.4x | -1826.6x | 19.9x |
Wed, 05 Apr 2023 | NT$49.9b | NT$2.7b | -NT$29,761,000.00 | 24.3x | -1676.3x | 18.8x |
Fri, 03 Mar 2023 | NT$51.2b | NT$2.7b | NT$85.3m | 19.8x | 600.4x | 19.1x |
Sun, 29 Jan 2023 | NT$45.3b | NT$2.7b | NT$85.3m | 19.1x | 531.4x | 16.9x |
Tue, 27 Dec 2022 | NT$50.6b | NT$2.7b | NT$85.3m | 19.2x | 593.1x | 18.9x |
Thu, 24 Nov 2022 | NT$53.0b | NT$2.7b | NT$139.5m | 18.5x | 379.8x | 19.8x |
Sat, 22 Oct 2022 | NT$43.7b | NT$3.0b | NT$482.8m | 23.1x | 90.5x | 14.6x |
Mon, 19 Sep 2022 | NT$49.0b | NT$3.0b | NT$482.8m | 27.5x | 101.4x | 16.3x |
Wed, 17 Aug 2022 | NT$41.8b | NT$3.0b | NT$491.5m | 37.3x | 85x | 13.9x |
Fri, 15 Jul 2022 | NT$38.6b | NT$3.1b | NT$325.1m | 37.3x | 118.8x | 12.6x |
Sun, 12 Jun 2022 | NT$40.4b | NT$3.1b | NT$325.1m | 36.7x | 124.4x | 13.2x |
Tue, 10 May 2022 | NT$29.7b | NT$2.9b | NT$80.8m | 27.3x | 367.2x | 10.1x |
Thu, 07 Apr 2022 | NT$33.3b | NT$3.2b | NT$164.4m | 27.8x | 202.7x | 10.5x |
Sat, 05 Mar 2022 | NT$35.5b | NT$3.0b | -NT$120,147,000.00 | 36.1x | -295.2x | 11.6x |
Mon, 31 Jan 2022 | NT$35.8b | NT$3.0b | -NT$120,147,000.00 | 34.3x | -298.1x | 11.8x |
Wed, 29 Dec 2021 | NT$38.4b | NT$3.0b | -NT$120,147,000.00 | 37.1x | -319.3x | 12.6x |
-319.3x
Which industries have driven the changes within the Taiwanese Healthcare industry?
TW Market | -2.11% | |
Healthcare | -1.31% | |
Life Sciences | 1.91% | |
Clinical Research and Equipment | 1.91% |
Which companies have driven the market over the last 7 days?
Company | Last Price | 7D | 1Y | Valuation | |
---|---|---|---|---|---|
6589 EirGenix | NT$71.70 | 5.4% +NT$1.1b | -28.7% | PS18.7x | |
6848 RBC Bioscience | NT$18.70 | 3.6% +NT$8.4m | 16.1% | PE14.1x |